Canaccord lowered the firm’s price target on Castle Biosciences (CSTL) to $37 from $42 and keeps a Buy rating on the shares. The firm said they delivered soid Q1 results and although they remain bullish on the company and believe the shares are undervalued, they recognize there is material risk to the company executing on its growth strategy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL:
- Castle Biosciences Reports Strong Q1 2025 Growth
- Castle Biosciences to acquire Capsulomics, terms undisclosed
- Castle Biosciences reports Q1 adjusted EPS (20c), consensus (7c)
- Castle Biosciences raises FY25 revenue view to $287M-$297M from $280M-$295M
- Castle Biosciences Reports 21% Revenue Increase in Q1 2025